I'm a title. Click here to edit me.
Raj Maturi, MD
Dr. Maturi published one of the first papers on the use of Avastin for the treatment of diabetic macular edema. He has been on the executive committee of the DRCR Network since 2009. He has been the protocol chairman for multiple nationwide retinal treatment protocols, most recently protocols U and W. He is co-author of a textbook on diabetic retinopathy treatments, as well as, participates in multiple clinic research trials with various pharmaceutical companies in an effort to advance the areas of treatment for all areas of vitreoretinal ophthalmology. He has over 100 publications to date and has conducted over 75 clinical trials.
Dr. Maturi graduated with honors from the New York University School of Medicine. He completed his ophthalmology residency training at the Baylor College of Medicine in Houston, Texas. Dr. Maturi then received the prestigious Heed Fellowship and completed an additional two-year fellowship at the University of Iowa, specializing in diseases of the retina and vitreous.
Thomas Hohman, PhD
Thomas Hohman, PhD leads clinical operations at Neurotech. He comes to Neurotech with more than 30 years of experience in research and drug development of novel therapeutics for retinal diseases. Thomas earned his Ph.D. at the University of California and completed fellowships at the National Heart Blood and Lung Institute and the National Eye Institute, both part of the NIH. Thomas began his career in drug development at Wyeth-Ayerst, where he led the aldose reductase inhibitor discovery program, advancing the clinical development of tolrestat as a treatment for diabetic neuropathy and retinopathy and progressing a second generation inhibitor, minalrestat, into a clinical proof-of-concept study. At Novartis, he was the Clinical Lead for the development of ranibizumab as a treatment for exudative AMD and diabetic macular edema (DME). As the Retina Therapeutic Area Head at Alcon, he designed and managed a natural history study of geographic atrophy (GA) and used the data to gain regulatory acceptance of a new primary endpoint for GA. In addition, he managed the preclinical and clinical evaluation of tandospirone, a serotonin 1A agonist, as a treatment for GA, and the preclinical and clinical development of a sustained release tyrosine kinase inhibitor as a treatment for diabetic macular edema (DME). As the Vice President of Retinal Translational Medicine and Drug Discovery at Allergan, he managed the preclinical and early clinical development of abicipar pegol, an anti-VEGF biologic, as a treatment for exudative AMD, and a sustained-release formulation of brimonidine as a treatment for GA. Following his retirement, he created a consulting company that evaluates the potential for success of new therapies and provides project guidance to small and large pharmaceutical companies as well as academic laboratories focused on developing novel therapies for retinal diseases, including inherited retinal dystrophies GA, DME, neovascular AMD, macular telangiectasia, retinal fibrosis and gene therapy.
Terry Dagnon began his career in the pharmaceutical industry as the Regulatory Affairs Manager for Physician Reliance Network Inc. (now known as U.S. Oncology) running the regulatory department of their oncology clinical research group. Terry continued his regulatory affairs career at Johnson & Johnson Medical Inc. and had global regulatory responsibility for the Wound Care, Skin Care and Tissue Engineering franchises. Terry was a Senior Vice President and General Manager of one of the businesses units at Dohmen Life Science Services (DLSS) which was acquired and became EVERSANA. Prior to joining DLSS Terry was the North America Head of Regulatory Affairs at Alcon a Novartis company. Terry had a number of global and domestic roles of increasing responsibility at Alcon over a 13-year period. Terry’s regulatory experience has involved responsibility from research to post-market with a large number of domestic and global investigational and marketing approvals in the pharmaceutical, biologic and medical device space. Terry is also very experienced in compliance and working with R&D, Marketing, Sales, Legal, Manufacturing, Quality and Supply Chain organizations. Prior to a career in the medical industry Terry served 11 years on active duty with the United States Army and was a SFC/E-7 18D Special Forces Green Beret Senior Non-Commissioned Officer. Terry and his wife Carole and their two sons reside in Colorado.